Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Dermatological Science|June 8, 2001
Pre-exposure with low-dose UVA suppresses lesion development and enhances Th1 response in BALB/c mice infected with Leishmania (Leishmania) amazonensisN M Khaskhely, M Maruno, A Takamiyagi, et al.
Ryumachi. [Rheumatism]|February 24, 2001
[A case with juvenile rheumatoid arthritis who developed cerebral vasculitis and venovascular hypertension]T Yamamoto, T Abe, M Mastuya, et al.
Ryumachi. [Rheumatism]|June 27, 1998
[A recovered case of SLE with central nervous system involvement who relapsed presenting new symptoms associated with development of serum anti-Sm antibody]K Hiura, T Abe, Y Hatanaka, et al.
Ryumachi. [Rheumatism]|August 29, 1998
[A case of systemic lupus erythematosus developed with intestinal perforation]I Ozeki, T Abe, H Sakai, et al.
British Journal of Cancer|November 28, 2013
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancerK Shitara, S Yuki, D Tahahari, et al.
Journal of Gastroenterology|May 6, 2015
Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trialN Kakushima, K Hori, H Ono, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)K Shimozaki, K Hirata, H Hayashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialC Morizane, T Okusaka, J Mizusawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)T Shirakawa, M Shimokawa, T Otsuka, et al.
Pageof 5